Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer

MDSC undergo metabolic reprogramming in the tumor resulting in an increased fatty acid beta oxidation that supports their immunosuppressive functions. Fatty acid oxidation inhibitors, used to treat coronary disease, significantly delayed tumor growth and had a significantly increased antitumor effect when combined with adoptive cell therapy or low dose chemotherapy.